Literature DB >> 12218165

Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60.

Francisco J Quintana1, Pnina Carmi, Felix Mor, Irun R Cohen.   

Abstract

Adjuvant arthritis (AA) is an autoimmune disease inducible in rats involving T cell reactivity to the mycobacterial 65-kDa heat shock protein (HSP65). HSP65-specific T cells cross-reactive with the mammalian 60-kDa heat shock protein (HSP60) are thought to participate in the modulation of AA. In this work we studied the effects on AA of DNA vaccination using constructs coding for HSP65 (pHSP65) or human HSP60 (pHSP60). We found that both constructs could inhibit AA, but that pHSP60 was more effective than pHSP65. The immune effects associated with specific DNA-induced suppression of AA were complex and included enhanced T cell proliferation to a variety of disease-associated Ags. Effective vaccination with HSP60 or HSP65 DNA led paradoxically to up-regulation of IFN-gamma secretion to HSP60 and, concomitantly, to down-regulation of IFN-gamma secretion to the P180-188 epitope of HSP65. There were also variable changes in the profiles of IL-10 secretion to different Ags. However, vaccination with pHSP60 or pHSP65 enhanced the production of TGFbeta1 to both HSP60 and HSP65 epitopes. Our results support a regulatory role for HSP60 autoreactivity in AA and demonstrate that this control mechanism can be activated by DNA vaccination with both HSP60 or HSP65.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218165     DOI: 10.4049/jimmunol.169.6.3422

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Authors:  Orly Gershoni-Yahalom; Shimon Landes; Smadar Kleiman-Shoval; David Ben-Nathan; Michal Kam; Bat-El Lachmi; Yevgeny Khinich; Michael Simanov; Itzhak Samina; Anat Eitan; Irun R Cohen; Bracha Rager-Zisman; Angel Porgador
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 2.  Qa-1 restriction of CD8+ suppressor T cells.

Authors:  Stefanie Sarantopoulos; Linrong Lu; Harvey Cantor
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

4.  Pediatric Sepsis - Part V: Extracellular Heat Shock Proteins: Alarmins for the Host Immune System.

Authors:  John S Giuliano; Patrick M Lahni; Hector R Wong; Derek S Wheeler
Journal:  Open Inflamm J       Date:  2011-10-07

5.  Beta-lactam antibiotics modulate T-cell functions and gene expression via covalent binding to cellular albumin.

Authors:  Felix Mor; Irun R Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 6.  Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines.

Authors:  Eugene Y Kim; Kamal D Moudgil
Journal:  Cytokine       Date:  2017-04-25       Impact factor: 3.861

Review 7.  The involvement of heat-shock proteins in the pathogenesis of autoimmune arthritis: a critical appraisal.

Authors:  Min-Nung Huang; Hua Yu; Kamal D Moudgil
Journal:  Semin Arthritis Rheum       Date:  2009-12-06       Impact factor: 5.532

8.  Regulation of autoimmune arthritis by self-heat-shock proteins.

Authors:  Kamal D Moudgil; Malarvizhi Durai
Journal:  Trends Immunol       Date:  2008-09       Impact factor: 16.687

Review 9.  Gene therapy of the rheumatic diseases: 1998 to 2008.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

10.  HSP60 as a target of anti-ergotypic regulatory T cells.

Authors:  Francisco J Quintana; Avishai Mimran; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  PLoS One       Date:  2008-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.